SLC2A1 and breast cancer: MiR-122 partially exhibits this effect and helps in metabolic reprogramming of the tumor microenvironment by downregulating its metabolic target genes PKM1/2 and GLUT1 in stromal cells in vitro and in vivo. MiR-122 has potential as a predictive marker and therapeutic target for BC metastasis [74].